Savara (NASDAQ:SVRA) Shares Down 5 5% theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Research analysts at JMP Securities assumed coverage on shares of Savara (NASDAQ:SVRA – Get Free Report) in a note issued to investors on Thursday, Briefing.com reports. The brokerage set an “outperform” rating and a $8.00 price target on the stock. JMP Securities’ price objective indicates a potential upside of 60.00% from the company’s previous close. […]
Savara Inc. , a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee.
On January 31, 2024, the.